Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2018–2023

RenalToolBox · Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2018-11-01 → 2023-04-30
Финансиране от ЕС
4 071 176 €
Участници
14
Схема
MSCA-ITN

Линиите свързват координатора с партньорите.

Накратко на български

Мезенхималните стволови клетки и нови методи за диагностика, като устройства за кожата и „бъбрек на чип“, се тестват при бъбречни заболявания. Това помага за по-добра оценка на безопасността и ефикасността на клетъчната терапия, за да се подобри качеството на живот на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Developing novel tools and technologies to assess the safety and efficacy of cell-based regenerative medicine therapies, focusing on kidney disease

Chronic diseases are the leading cause of mortality, with chronic kidney disease (CKD) affecting >10% of the population worldwide. There is a need for therapies that can impact the survival and quality of life of CKD patients. Therapies based on mesenchymal stromal cells (MSCs) are showing promise in rodent models of kidney disease but before they can be used for CKD we need: (i) cost-effective and convenient methods for diagnosing CKD, (ii) reliable data on the safety and efficacy of MSC therapies and (iii) a better understanding of which MSCs have greatest therapeutic potential and how they might act to prevent kidney disease. Our three research objectives and conclusions were: 1. Develop novel tools for diagnosing kidney disease and assessing renal function: a new device to measure kidney function quickly and easily was devised. This was based on the excretion/absorption of tracers given intravenously, with the measurements obtained via a device attached to the skin. We also identified biomarkers that can indicate the health/disease state of the kidney, to monitor the progression and regression of renal disease more accurately. Finally, a kidney-on-a-chip device for the testing of tracers and MSC efficacy was developed. 2. Develop and apply cutting-edge imaging technologies to evaluate the safety and efficacy of MSCs in a rodent model of kidney disease: to assess safety, we applied complementary imaging technologies and probes to monitor the biodistribution and fate of MSCs in animals and, at study end-points, in tissues. For efficacy, we applied novel imaging strategies and analysis tools to monitor renal function and structure longitudinally in rodents with an ischaemia reperfusion injury (IRI). Intact organs were analysed post-mortem with novel microscopy ‘clearing’ techniques to validate the in vivo biodistribution results, accurately quantify the extent of morphological damage and determine potential mechanisms by which MSCs act. 3. Establish the optimal source of MSCs, develop a matrix of potency assays and explore therapeutic mechanisms: we compared the properties and therapeutic potential of MSCs derived from different tissues (bone marrow, adipose and umbilical cord) to identify differences in their potential to treat kidney injury. We also looked at the properties of extracellular vesicles (EVs), a product of MSC culture, and their therapeutic effects.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The RenalToolBox ITN comprises a team of world-leading clinicians, scientists and industrialists from academia and private enterprise whose common goal is to develop innovative medical devices and imaging technologies to expedite the translation of cell-based regenerative medicine therapies (RMTs) to the clinic. The target disease for RenalToolBox is kidney disease, the incidence of which is increasing annually. The ITN provides an excellent framework for training 15 early stage researchers (ESRs) in a range of technological, entrepreneurial and transferable skills that will not only enhance their career prospects, but will also boost European scientific excellence and business innovation. By the end of the programme, the ESRs will have benefitted from a comprehensive multidisciplinary and multi-sectoral training experience that will equip them to expedite progress in the emerging supradisciplinary fields of biomedical devices, bio-imaging, cellular therapeutics and regenerative medicine. The research training objectives are as follows: 1. Train the young researchers in the development of diagnostic devices and novel tracers for monitoring renal function. 2. Apply cutting-edge imaging technologies to evaluate the safety and efficacy of novel cell-based RMTs in a rodent model of kidney disease. 3. Assess the safety and efficacy of different sources of mesenchymal stromal cells and explore the mechanisms whereby these cells can ameliorate kidney disease. This comprehensive training programme will endow the young researchers with the necessary scientific and industrial skills to ensure their employability and readiness to engage and lead the next European generation of scientists-entrepreneurs.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз